

Medical Marijuana Qualifying Condition Summary and Decision

Condition to be added: Female Orgasmic Disorder, ICD-10 Code F 52.31

Date received: July 23, 2024

End of public comment period: October 14, 2024, after the September 11, 2024, Public Hearing

End of 120 days from date of receipt: November 20, 2024

Petition decision: Approved _____ Denied ✓

Comments:

I have reviewed the articles provided by the petitioner, comments made by the public, additional articles and reports on female orgasmic disorder and marijuana, and I have reviewed the comments of the Arkansas Surgeon General and Arkansas Department of Health Medical Director for Women's Health, Dr. Kay Chandler, MD, FACOG.

Jennifer Dillaha, MD

Signature

November 19, 2024

Date

Medical Marijuana addition of Female Orgasmic Disorder as a qualifying condition

Based on my review of the public comments, the articles included in the petitioner's packet, additional articles and reports related to female orgasmic disorder/female sexual function and use of marijuana, I find the current scientific evidence related to the use of medical marijuana to treat female orgasmic disorder is insufficient to support the use of medical marijuana for the treatment of Female Orgasmic Disorder. Randomized, placebo-controlled trials with assessment of therapeutic dose are still needed to assess the risk and benefits.

The most relevant articles in the packet are also those most recently published. They report the results of survey studies related to self-reported effects of marijuana use on Female Orgasmic Disorder as defined by the orgasm subscale of the Female Sexual Function Index. Overall, the results indicate a positive association between use of marijuana and enhanced sexual experience. These findings are based on self-reported information using convenience samples of subjects without the measurement of dose. Additional review of existing literature indicates an association of higher doses of marijuana with a negative effect on female sexual function. There were no studies in the packet that reported results of randomized, well-controlled clinical trials for treatment of Female Orgasmic Disorder, and no clinical trials were listed at clinicaltrials.gov.

Jennifer Dillaha, MD



Sarah Huckabee Sanders
GOVERNOR

Renee Mallory
SECRETARY OF HEALTH

Jennifer Dillaha
DIRECTOR

Date: 11/10/2024

Jennifer Dillaha, MD
Director and State Health Officer
Arkansas Department of Health
4815 W. Markham Street, Slot 39
Little Rock, AR 72205

RE: Female Orgasmic Disorder as Qualifying Medical Condition for medical marijuana use

Dear Dr. Dillaha

I do not recommend adding female orgasmic disorder to the list of Qualifying Medical Conditions specific to medical marijuana use.

While current articles reporting on self reported survey data indicate an overall positive association between cannabis use and female orgasmic function, there are no randomized placebo-controlled studies that control for exact dosing and timing of use. Current data has shown that cannabis may have both positive and negative effects on sexual function depending on dosage. More rigorous studies are needed to provide a comprehensive understanding of the effects of marijuana on female sexual function.

Sincerely,


Kay H. Chandler, MD, FACOG

Arkansas Department of Health Women's Health Medical Director

Arkansas Department of Health
4815 West Markham St. • Little Rock, AR 72205

HEALTHY.ARKANSAS.GOV